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SUMMARY
To investigate cross-colonization with and persistence oi Pseudomonas aeruginosa
in cystic fibrosis (CF), 181 isolates from 76 CF patients were typed using a P.
aeruginosa-specific DNA probe. Whereas sibling pairs predominantly harboured
genotypically identical P. aeruginosa strains, all of the other patients harboured
different strains. Seventy-nine per cent (22/31) of the infected CF patients
harboured the same strains at the beginning and the end of a summer camp. A
change of strains was seen in 10% (3/31) of the patients at the end of the camp.
Forty-six per cent (6/13) of the patients who were apparently initially uninfected,
acquired P. aeruginosa by the end of the period. Genotyping proved that strain
change or acquisition was due to cross-colonization in four of nine cases. Very little
P. aeruginosa was isolated from the inanimate environment. Persistence of P.
aeruginosa after a temporary loss due to antibiotic therapy was seen in 12/16
paired patient strains before and after antibiotic therapy. Thus, suppression
followed a flare-up seemed to occur in these patients rather than eradication and
a new infection. When 35 patients were followed over a period of 6 months, 7
(20%) changed the strain in their sputum. Only one of 43 patients harboured two
different P. aeruginosa strains simultaneously over a long period.
INTRODUCTION
In patients with cystic fibrosis (CF) Pseudomonas aeruginosa is the predominant
bacterium associated with pulmonary infection (Hoiby, 1982). This infection is
thought to be crucial to patient life expectancies since specific antibiotic therapy
normally fails to eradicate the organism from the airways and since a close
relationship exists between chronic P. aeruginosa infection and poor clinical status
and prognosis (Hoiby, Doring & Schiotz, 1986). The sources from which CF
patients acquire this opportunistic pathogen and the routes of infection are largely
a matter of speculation. Previous epidemiological studies yielded conflicting
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206 CHRISTIANE WOLZ AND OTHERS
results concerning nosocomial cross-colonization and cross-infection between CF
patients and the role of the inanimate environment in this process (Hoiby &
Rosendal, 1980; Kelly et al. 1982; Speert & Campbell, 1987; Thomassen et al.
1985; Zimakoff et al. 1983; Speert, Lawton & Damm, 1982; Laraya-Cuasay,
Cundy & Huang, 1976; Bergan & Hoiby, 1975; Seale et al. 1979; Zierdt &
Williams, 1975; Pedersen et al. 1986).
Until recently, epidemiological studies on P. aeruginosa in CF have been
hampered by the lack of a stable strain specific marker, since the classic typing
methods such as pyocin, bacteriophage, and serotyping have considerable
limitations for P. aeruginosa isolates. The development of a DNA probe consisting
of the upstream region of the 'exotoxin A' (ExoA) structural gene off. aeruginosa
has greatly facilitated investigations in this field (Vasil, Chamberlain & Grant,
1986). Using this probe in Southern blot analysis, more than 100 P. aeruginosa
strains have been differentiated and isolates which were indistinguishable by
serotyping, biotyping and antibiograms were easily distinguished (Ogle et al.
1987).
In the present study a similar DNA probe containing the ExoA structural gene
and the adjacent upstream region was used to investigate several open questions
in the epidemiology of P. aeruginosa in CF. Is cross-infection likely to occur
between CF patients in a clinic or at home ? Does the environment represent a
major source for acquiring P. aeruginosa lung infections ? Is a temporary 'loss' of
P. aeruginosa after antibiotic therapy the result of bacterial eradication or
suppression ? How many strains are harboured by a CF patient at the same time
in the sputum ? How long can a given strain be detected in the sputum ? We
present evidence that (1) cross-infection in a CF clinic as well as between siblings
at home may occur, (2) P. aeruginosa is rarely found in the inanimate environment,
(3) P. aeruginosa is not eradicated but only suppressed after successful antibiotic
therapy, (4) CF patients normally harbour only one P. aeruginosa strain in their
sputa at a time, and (5) after 6 months 26% of the infected patients had changed
their P. aeruginosa sputum genotype.
MATERIAL AND METHODS
Subjects
For P. aeruginosa typing, sputa from 46 CF patients at the beginning (43 sputa)
and the end (44 sputa) of a 6-week recreational stay at the CF clinic Satteldiine,
Amrum, Federal Republic of Germany, and from 4-10 months later (35 sputa)
were obtained. Patients 1-15, 16-35 and 36-46 were together at the same time in
the clinic (mean age, 14-7 years; range, 5-32 years). Additionally, P. aeruginosa
isolates or whole sputum was obtained from 12 European CF sibling pairs and
from 11 CF patients before and after antibiotic therapy. Sera were obtained from
7 CF patients. Diagnosis of CF was based on accepted criteria including
significantly increased sweat electrolyte levels (Wood, Boat & Doershuk, 1976).
Informed consent was obtained from patients, parents or guardians.
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Clinical score
To evaluate the patients' clinical state, a scoring system was developed based on
the following lung function parameters: airway resistance, intra-thoracic gas
volume, the ratio of residual volume to total lung capacity, forced expired volume
in 1 s, and inspiratory vital capacity. Additionally, po values were incorporated.
The patients' weight and height were evaluated using the somatogram developed
by Vogt (1959). The divergence of the parameters from normal values were graded
from 0-10 and the seven figures were added up. The patients were classified as
belonging to group A (0-15, mild); B (16-35, evident) or C (> 36, severe).
Specimen collection
In order to isolate P. aeruginosa from inanimate surfaces in the CF clinic at
Amrum and in the homes of three families with P. aeruginosa-miecte A CF children.
Rodac plates (Greiner, Nurtingen, Federal Republic of Germany) with cetrimide
agar (Difco, Detroit, USA) were used. A total of 290 plates was rolled over beds,
tables, toys, washing basins, door-handles, toilet seats, swimming pools,
examining couches, carpets and indoor plants. Air samples in the CF clinic and in
family homes were obtained by exposing open Rodac plates for 1-8 h in various
rooms and using a slit sampler with a rotating cetrimide agar plate (35 1/h)
(Heinrich Burghart, Wedel, Federal Republic of Germany). If the patients
produced sputum, it was solubilized in 5 ml of trypticase soy broth (TSB) (Difco),
incubated at 37 °C overnight, and cultured on cetrimide agar plates for 24-28 h;
5 ml TSB supplemented with 25 % glycerol (w/w) was added to the plates, all
bacterial colonies were scraped from the agar using a pipette and the suspensions
were stored at —70 °C until use. From three sputum specimens six single colonies
with non-mucoid and mucoid morphologies were separately isolated. Rodac plates
were incubated at 37 °C for 48 h. The P. aeruginosa isolates were characterized by
colony morphology, biochemical reactions, growth at 42 °C, and genotyping.
Genotyping of P. aeruginosa
Genotyping of P. aeruginosa with the ExoA DNA probe was carried out as
described previously with some modifications (Vasil, Chamberlain & Grant, 1986).
Chromosomal DNA was isolated using standard methods (Marmur, 1960). The
purified DNA (1-2 /ig) was digested with the restriction endonucleases Bgl II,
Sal I and Xho I, electrophoresed through a 0-6% agarose gel and transferred to a
nylon membrane (Pall, Dreieich, Federal Republic of Germany) using the method
of Southern (1975). The Escherichia coli plasmid pCMtox (Vasil, Chamberlain &
Grant, 1986) (Figure 1) was isolated (Maniatis, Fritsch & Sambrock, 1982), and
labeled with biotin-11-dUTP (Gibco, Bethesda, USA) by nick translation. In
modificaton of the original method, the whole pCMtox plasmid was used for
hybridization. The nylon membranes were prehybridized for 2 h, followed by
hybridization at 42 °C for 18 h using a hybridization solution of 45% (vol/vol)
formamide, 5 x SSC, 1 x Denhardt's solution, 20 HIM sodium phosphate, pH 6.5,
5% dextran sulfate and 0.2 mg/ml sheared herring sperm DNA. Streptavidin/
alkaline phosphatase reagent was added to the washed and blocked membranes.
The membranes were then developed using BCIP and NBT (Gibco-BRL,
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Fig. 1. pCMtox plasmid containing the ExoA structural gene and the variable
upstream region of P. aeruginosa which is used for probing P. aeruginosa strains.
Bethesda, USA and Serva, Heidelberg, Federal Republic of Germany) according
to the manufacturers' instructions. Isolates were compared visually for differences
in probe-reactive fragments. Fragment size was determined by comparison with
labelled lambda Hindlll fragments. Two isolates were considered different strains
if one or more of the three strain-specific, probe-reactive fragments differed in size.
In cases of doubt, when strains were run on different gels and the size of respective
fragments showed differences of less than O5 kb the strains were re-examined on
one gel. Due to the reduced separation of DNA fragments > 10 kb in the 0-6%
agarose gel, genotyping of strains with probe-reactive fragments of this size may
be unprecise. However, the use of three restriction enzymes for DNA digestion
may counteract this difficulty.
Radioimmunoassays
Detection of antibodies against the ExoA, elastase (Ela) and alkaline protease
(AP) of P. aeruginosa in the sera from CF patients was performed by
radioimmunoassay as described elsewhere (Doring et al. 1983; Doring et al.
1985).
RESULTS
The whole pCMtox plasmid was used for hybridization (Figure 1) for several
reasons: first, the isolation of the Pst I-Nru I fragment resulted in low yield and
reduced sensitivity. Second, the use of the whole pCMtox plasmid allows one to
identify P. aeniginosa strains in cases where the variable region or the ExoA gene
is missing. Hybridization patterns of P. aeruginosa DNA from 5 CF patients are
seen in Fig. 2. Typically, there are two (Bgl II, Xho I) or three (Sal I) labeled
fragments for each strain, revealing the variable region upstream of the ExoA gene
and the constant region within and downstream of the ExoA gene.
One hundred and eighty-one isolates from 76 CF patients were typed using this
DNA probe. Seven of 12 sibling pairs harboured genotypically identical P.
aeruginosa strains (data not shown). All of the other patients harboured different
strains revealing the discriminatory power of the method.
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Fig. 2. DXA hybridization pattern of P. aeruginosa strains from CF patients from the
beginning (a) and/or the end (6) of a summer eamp. Lane 1, patient 40b; lane 2, patient
lib; lane 3. patient 12a; lane 4, patient 36a; lane 5, patient 36b. Purified P. aeruginosa
DXA (l-2/«g) was digested with Bgl II. »SW I and Xho I, electrophoresed through a
0-6 % agarose gel and transferred to a nylon membrane using the method developed by
Southern. The isolated pCMtox plasmid was labeled with biotin-11-dUTP by nick-
translation. The nylon membranes were prehybridized for 2 h, followed by hy-
bridization at 42 °(* for 18 h using a hybridization solution of 45% (vol/vol) formamide,
ox.SNC 1 x Denhardt's solution. 20 HIM sodium phosphate, pH 6.5, 5% dextran
sulphate and 0.2 mg/ml sheared herring sperm DNA. Streptavidin/alkaline phos-
phatase reagent was added to the washed and blocked membrane. The membranes
were then developed using BCIP and NBT. Isolates were compared visually for
differences in probe-reactive fragments. Fragment size was determined by comparison
with biotin-labelled lambda Hindlll fragments. Two isolates were considered different
strains if one or more of the three strain-specific, probe-reactive fragments differed in
size. In cases of doubt, when strains were run on different gels and the size of respective
fragments showed differences of less than 0.5 kb, the strains were reexamined on one
gel.
Cross-colonization in a cystic fibrosis clinic.
Twenty-two patients (71 %) of the 31 infected patients entering the CF clinic at
Amrum carried the same / ' . aeruginosa strains at the beginning and end of the
period, whereas a change of strains was seen in 10% of the patients (patients 25,
26, 40; Table 1). Genotyping revealed that strains 26b and 40b were identical to
strains found in patients 17 and 41. Six (46%) of the 13 uninfected patients
entering the clinic (patients 10, 11, 27, 31-33; Table 1) left the clinic harbouring
P. aeruginosa in their sputa. Genotyping revealed that strains from patients 11
and 12 (Fig. 2) and from patients 33 and 34 were identieal. Thus, cross-
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P. aeruginosa in cystic fibrosis 211
colonization was evident in 4 patients (patients 26, 40, 11, 33). In total, 9 patients
were either newly colonized or changed their strains.
The strains of the newly colonized patients 10, 25, 27, 31, and 32 were not
identical to any of the other patient strains. In order to investigate whether these
strains were derived from the inanimate environment in the clinic, 230 samples
from various clinic sites were taken during the third recreation course (patients
36-46). Only two identical P. aeruginosa isolates were recovered from these sites
which could not be traced back to a patient strain. Thus, the spreading of P.
aeruginosa from infected patients in the clinic was observed but contamination of
the inanimate sites in the clinic was minimal.
In order to rule out that the newly colonized patients already carried the strains
when entering the clinic, antibody titers of these patients to the P. aeruginosa
antigens alkaline protease, elastase and ExoA were determined. No significant
titers (< 10) were found in sera at the beginning of the clinic stay. At the end of
the clinic stay two patients were antibody-positive to the three antigens (data not
shown). This result supports the theory that a new colonization took place during
the stay. Furthermore, no history of P. aeruginosa infection was reported in the
patients' clinical sheets. However, it cannot entirely be ruled out that the patients
were already colonized with P. aeruginosa before entering the clinic, since
antibody titers to the investigated antigens become positive an average of 6—15
months after the onset of colonization (Doring & Hoiby, 1983).
Persistence of P. aeruginosa
In order to investigate whether the temporary 'loss' of P. aeruginosa after
antibiotic therapy in some patients resulted from bacterial eradication or
suppression, P. aeruginosa isolates were genotyped before and after the period in
which they were undetectable in the sputum. Genotypically identical 'before-and-
after' isolate pairs were obtained from 3 of 5 patients who were treated with
antibiotics at the CF clinic Satteldiine and 'lost' their strains (patients 12, 13, 41;
Table 1) and from 9 of the 11 CF patients treated at the Inselhospital in Bern,
Switzerland (data not shown) (Schaad et al. 1987). Thus, the reappearance of P.
aeruginosa after a temporary loss due to intensive antibiotic therapy is not caused
by reinfection with a new strain but is probably due to the effective suppression
of large numbers of P. aeruginosa in the sputa.
The persistence of the P. aeruginosa genotypes in CF patients was further
assessed by investigating the sputum samples of 35 patients 4-10 months after the
recreation period at the CF clinic. Twenty (57 %) of the patients harboured strains
identical to those they carried before, including 4 (patients 25, 32, 33, 40) of the
9 newly colonized patients In the remaining 12 patients a change of the P.
aeruginosa genotype or a strain loss was seen (Table 1). Strain change or loss was
independent of any change in the clinical state of the patients (Table 1). The
analysis of six single colonies of P. aeruginosa with non-mucoid and mucoid
morphology from three patients revealed that in these patients only one strain was
present at a time. Similarly, when all P. aeruginosa sputum isolates were used for
genotyping, the majority of patients revealed two DNA hybridization bands on
Southern blots indicating the existence of only one P. aeruginosa strain. Only one
patient (25; Table 1) was colonized with two different strains simultaneously over
a long period.
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DISCUSSION
CF patients suffering from chronic P. aeruginosa lung infections may spread the
bacteria to the environment and thus may be a risk for other infected or
uninfected CF patients who live in close contact with them. Several previous
studies using classical typing methods for P. aeruginosa addressed the question of
where CF patients acquire P. aeruginosa and whether cross-infection between
patients occurs. Although cross-infection does not seem to be a major problem in
some hospitals (Hardy et al. 1986), transient cross-colonization (Speert & Campbell,
1987) and an epidemic spread of multiresistant P. aeruginosa between CF patients
was observed in two hospital settings (H0iby & Rosendal, 1980; Zimakoff et al.
1983; Bergan & Hoiby, 1975; Zierdt & Williams, 1975; Pedersen et al. 1986).
However, the inaccuracies of the older typing methods made an interpretion of the
data difficult. Thus, loss of high molcular weight lipopolysaccharide in mucoid P.
aeruginosa isolates from CF patients render strains non-typable with O-specific
antibodies. Furthermore, CF isolates are less sensitive to lysis by typing phages
than are those from other patients (Pitt, 1988). Lastly, different pyocin patterns
occur with changes in bacterial metabolism and antibiotic therapy may alter
pyocin production patterns (Thomassen. Demko & Doershuk, 1987). The
present study corroborates previous results concerning the usefulness of the
ExoA-DHA probe for epidemiological studies on P. aeruginosa (Ogle et al. 1987).
Although genotyping is generally much more time-consuming than classical
typing methods such as phage typing, pyocin typing or serotyping, the
discriminatory ability of the method is higher. Nevertheless, a comparative study
of all major typing methods for CF and non-CF P. aeruginosa strains seems to be
valuable.
Previous studies suggested that siblings may harbour the same strain (Laraya-
Cuasay, Cundy & Huang, 1976; Pedersen et al. 1986; Ogle et al. 1987). However,
the numbers of sibling pairs investigated were small or the results based on the
serotyping and/or pyocin typing of P. aeruginosa strains. The results of the
present study on 12 sibling pairs show that the majority of CF siblings share the
same P. aeruginosa strain. The question still arises whether this reflects cross-
infection from patient to patient or whether the sibling strain is derived from a
common source in the environment of the patients.
In contrast to the siblings, all of the infected CF patients living together at the
Satteldiine clinic harboured different strains before entering the clinic. However at
the end of the period four patients became colonized with other patients' strains.
In view of the finding that 46% of the uninfected patients harboured P.
aeruginosa in their sputa at the end of the period, the results support previous
studies (Hoiby & Rosendal, 1980; Zimakoff et al. 1983; Zierdt & Williams, 1975;
Pedersen et al. 1986), suggesting cross-colonization between CF patients not only
at home but also in the clinic. The routes by which such a high percentage of
patients had been newly colonized during the clinic stay remain to be clarified.
One source for contamination with P. aeruginosa may be the inanimate
environment. In previous studies P. aeruginosa (Speert & Campbell, 1987;
Pedersen et al. 1986) and P. cepacia (Hardy et al. 1986) were rarely recovered from
the inanimate environment in CF clinics. A similar result was obtained in the
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present study revealing little contamination on dry surfaces. Also in the CF
families, not a single P. aeruginosa isolate was found. Several facts may be
responsible for this surprising result: first, the selective P. aeruginosa isolation
medium cetrimide used in the present study may suppress P. aeruginosa strains
from CF (Fonseca, MacDougall & Pitt, 1986); second, the survival rate of P.
aeruginosa on dry surfaces may be short; third, other places than those
investigated may represent important sources for P. aeruginosa in the en-
vironment.
One interesting finding of the present study is that CF patients harboured only
one P. aeruginosa strain in their sputum at a time and that this strain persisted
in the majority of patients over 6 months both with and without antibiotic
therapy. Larger and longer studies are needed to explain the P. aeruginosa
genotype change in 20% of the CF patients and correlate it with bacterial
virulence or bacterial growth in the CF respiratory tract.
We are indebted to Dr Jeanette Dankert-Roelse, University of Groningen, The
Netherlands, and Professor Niels Hoiby, Statens Serum Institute, Copenhagen,
Denmark for supplying us with clinical isolates of P. aeruginosa from CF siblings.
We thank Diana Blaurock for translation. The study was supported by a grant for
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